Back to results
US 2019/0055602 A1Published application
Systems and methods to diagnose sarcoidosis and identify markers of the condition
AssigneesWayne State University, Henry Ford Health System
InventorsLobelia Samavati, Harvinder S. Talwar, Rita Rosati, Felix Fernandez-Madrid, Jia Li
Life of this patent
Estimating the term…
Abstract
Systems and methods to diagnose sarcoidosis are described. In addition to diagnosing sarcoidosis, the systems and methods can distinguish sarcoidosis from tuberculosis. Further disclosed is a cDNA library and methods of its use for reliably identifying sarcoidosis markers.
Claims21
A kit comprising:
- a protein that binds Small inducible cytokine A21 precursor (CCL21);
- Methionine aminopeptidase 1 (Metap1);
- Activated RNA polymerase II transcription cofactor variant 4 (PC4);
- RNA methyltransferase (CLI_3190);
- Tumor necrosis factor receptor superfamily member 21 precursor (TNFRSF21);
- Monocyte differentiation antigen CD14 (CD14);
- DnaJ (Hsp40) homolog subfamily C member 1 precursor (DNAJC1);
- Amyloid R A4 precursor protein binding family B member 1-interacting protein (APBB1);
- Fibroblast growth factor binding protein 2 precursor (FGFBP-2);
- or SH3 domain-containing YSC84 like protein 1 (SH3YL1) and a detectable label;
- a nucleic acid that binds a gene encoding CCL21;
- Metap1;
- PC4;
- CLI 3190;
- TNFRSF21;
- DNAJC1;
- APBB1;
- FGFBP-2;
- or SH3YL 1 and a detectable label;
- a protein that binds Ferredoxin (Fed A);
- WDFY3 protein (WDFY3);
- Membrane protein (MFS);
- Leucine rich PPR-motif containing protein (LRPPRC);
- HLA-DR alpha (HLA-DR);
- Transketolase (TKT);
- Dihydroxy acid dehydratase (Rv0189C);
- Chain A Mycobacterium tuberculosis (BfrA);
- Disabled homolog 2 isoform 2 (DAB2);
- or Transcription elongation factor B polypeptide 2 isoform (Homo sapiens) (TCEB2) and a detectable label;
- or
- a nucleic acid that binds a gene encoding Fed A;
- WDFY3;
- MFS;
- LRPPRC;
- HLA-DR;
- TKT;
- Rv0189C;
- BfrA;
- DAB2;
- or TCEB2 and a detectable label.
37 more elements
2-4. (canceled)
A method, comprising
- obtaining a sample from the subject;
- assaying the sample for
- one or more markers selected from CCL21;
- Metap1;
- PC4;
- CLI_3190;
- TNFRSF21;
- CD14;
- DNAJC1;
- APBB1;
- FGFBP-2;
- or SH3YL1;
- or
- one or markers selected from Fed A;
- WDFY3;
- MFS;
- LRPPRC;
- HLA-DR;
- TKT;
- Rv0189C;
- BfrA;
- DAB2;
- or TCEB2.
20 more elements
(canceled)
15-36. (canceled)
A microarray comprising:
- a protein that binds CCL21;
- Metap1;
- PC4;
- CLI_3190;
- TNFRSF21;
- CD14;
- DNAJC1;
- APBB1;
- FGFBP-2;
- or SH3YL1;
- a protein that binds Fed A;
- WDFY3;
- MFS;
- LRPPRC;
- HLA-DR;
- TKT;
- Rv0189C;
- BfrA;
- DAB2;
- or TCEB2;
- a nucleic acid that binds to a gene encoding CCL21;
- Metap1;
- PC4;
- CLI 3190;
- TNFRSF21;
- CD14;
- DNAJC1;
- APBB1;
- FGFBP-2;
- or SH3YL1;
- a nucleic acid that binds a gene encoding Fed A;
- WDFY3;
- MFS;
- LRPPRC;
- HLA-DR;
- TKT;
- Rv0189C;
- BfrA;
- DAB2;
- or TCEB2;
- one or more of CCL21;
- Metap1;
- PC4;
- CLI 3190;
- TNFRSF21;
- CD14;
- DNAJC1;
- APBB1;
- FGFBP-2;
- or SH3YL1;
- or
- one or more of Fed A;
- WDFY3;
- MFS;
- LRPPRC;
- HLA-DR;
- TKT;
- Rv0189C;
- BfrA;
- DAB2;
- or TCEB2.
58 more elements
38-42. (canceled)
The method of 47, which is further a method of directing an appropriate treatment regimen for the subject, the method further comprising:
- directing treatment with a sarcoidosis treatment if the subject is diagnosed as having sarcoidosis,
- directing treatment with a tuberculosis treatment if the subject is diagnosed as having tuberculosis, or
- directing further medical analysis if the subject is diagnosed as healthy and the subject's symptoms suggest further analysis.
Dependencies are inferred from the claim text.